CI
VRTX icon

Cavalier Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Cavalier Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,807
Closed -$2.79M – 114
2025
Q3 		$2.79M Buy
7,807
+372
+5% +$155K 0.23% 56
2025
Q2 		$3.31M Sell
7,435
-138
-2% -$63.6K 1% 24
2025
Q1 		$3.67M Sell
7,573
-12
-0.2% -$5.59K 1.25% 24
2024
Q4 		$3.05M Buy
7,585
+288
+4% +$133K 1.02% 20
2024
Q3 		$3.39M Buy
7,297
+414
+6% +$199K 1.04% 22
2024
Q2 		$3.23M Buy
6,883
+186
+3% +$80.7K 0.99% 23
2024
Q1 		$2.8M Buy
6,697
+337
+5% +$142K 1.02% 26
2023
Q4 		$2.59M Buy
6,360
+144
+2% +$53.2K 0.95% 29
2023
Q3 		$2.16M Buy
6,216
+210
+3% +$73.4K 0.85% 34
2023
Q2 		$2.11M Buy
+6,006
New +$2.02M 0.77% 34

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Cavalier Investments's VRTX Position: Q4 2025 in Review

Cavalier Investments sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 7,807 shares — an estimated $2.79M sold.

Cavalier Investments first reported a position in VRTX in Q2 2023 and held it in 10 quarters. The position peaked at $3.67M in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Cavalier Investments reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Cavalier Investments sold 7,807 Vertex Pharmaceuticals shares in Q4 2025, an estimated $2.79M.
  • Cavalier Investments first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Cavalier Investments's Vertex Pharmaceuticals position peaked at $3.67M in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Cavalier Investments's 13F filing for Q4 2025, filed 13 Feb 2026.